Total cost, £ | UTIs resolved, n | Cost per UTI resolved, £ | |||||
---|---|---|---|---|---|---|---|
Baseline sensitivity analyses | Scenarios | ||||||
Probabilistic | Deterministic | A | B | C | |||
Trimethoprim 200 mg twice daily for 7 days | 60 | 857 | 70 | 69 | 69 | 91 | 73 |
Fosfomycin 3 g once | 65 | 842 | 78 | 77 | 80 | 77 | |
Nitrofurantoin (MR) 100 mg twice daily for 7 days | 69 | 849 | 82 | 81 | 87 | 84 | 100 |
Pivmecillinam 200 mg twice daily for 7 days | 67 | 766 | 88 | 96 | 98 | 99 | |
Nitrofurantoin 50 mg four times a day for 7 days | 78 | 799 | 98 | 97 | 104 | 101 | |
Pivmecillinam 200 mg three times a day for 7 days | 78 | 753 | 103 | 103 | 106 | 106 | |
Pivmecillinam 400 mg twice daily for 3 days | 78 | 704 | 111 | 111 | 114 | 114 | |
Trimethoprim 200 mg once | 81 | 609 | 133 | 131 | 130 | 161 | |
Nitrofurantoin 100 mg four times a day for 3 days | 87 | 631 | 138 | 139 | 147 | 144 |
Note: treatments ordered by lowest cost per UTI resolved.
Baseline analysis compared with the two deterministic scenarios tested: A = resistance rates from pathogens other than E. coli; B = updated resistance measures for trimethoprim, nitrofurantoin, and pivmecillinam; and C = estimated effectiveness for 3-day dosing, which is in line with the current guidance from Public Health England for use of these treatments. MR = modified release. UTI = urinary tract infection.